Global NGS-based RNA-seq Market

1 INTRODUCTION OF GLOBAL NGS-BASED RNA-SEQ MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL NGS-BASED RNA-SEQMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL NGS-BASED RNA-SEQ MARKET, BY END USER:
5.1 Research Centers and Academic & Government Institutes
5.2 Hospitals & Clinics
5.3 Pharmaceutical & Biotechnology Companies
5.4 Other End Users

6 GLOBAL NGS-BASED RNA-SEQ MARKET, BY APPLICATION:
6.1 Expression Profiling Analysis
6.2 Small RNA Sequencing
6.3 De Novo Transcriptome Assembly
6.4 Variant Calling and Transcriptome Epigenetics

7 GLOBAL NGS-BASED RNA-SEQ MARKET, BY TECHNOLOGY:
7.1 Sequencing By Synthesis
7.2 Ion Semiconductor Sequencing
7.3 Single-Molecule Real-Time Sequencing
7.4 Nanopore Sequencing

8 GLOBAL NGS-BASED RNA-SEQ MARKET, BY PRODUCT AND SERVICES:
8.1 Sample Preparation
8.1.1 Sample Preparation, By Workflow Step
8.1.1.1 Fragmentation, End Repair, and Size Selection
8.1.1.2 Library Preparation and Target Enrichment
8.1.1.3 Quality Control
8.1.2 Sample Preparation, By Method
8.1.2.1 Manual Sample Preparation
8.1.2.2 Microfluidic Sample Preparation
8.1.2.3 Robotic Liquid Handling Sample
8.1.3 Sequencing Platforms and Consumables
8.1.4 Sequencing Services
8.1.5 Data Analysis, Storage, and Management
9 GLOBAL NGS-BASED RNA-SEQMARKET, BY GEOGRAPHY
9.1 Overview
9.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico
9.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest of Europe
9.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific
9.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.5.1 Brazil
9.5.2 Argentina
9.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

10 GLOBAL NGS-BASED RNA-SEQMARKETCOMPETITIVE LANDSCAPE
10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies

11 COMPANY PROFILES
11.1 Illumina, Inc.
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments

11.2 Thermo Fisher Scientific Inc.
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments

11.3 Pacific Biosciences of California, Inc.
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments

11.4 Qaigen N.V.
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments

11.5 F. Hoffmann-La Roche AG
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments

11.6 Agilent Technologies, Inc.
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments

11.7 BGI (Beijing Genomics Institute)
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments

11.8 Oxford Nanopore Technologies, Ltd
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments

11.9 Perkinelmer, Inc.
11.9.1 Overview
11.9.2 Financial Performance
11.9.3 Product Outlook
11.9.4 Key Developments

11.10 Eurofins Scientific
11.10.1 Overview
11.10.2 Financial Performance
11.10.3 Product Outlook
11.10.4 Key Developments

11.11 Gatc Biotech AG
11.11.1 Overview
11.11.2 Financial Performance
11.11.3 Product Outlook
11.11.4 Key Developments

11.12 Macrogen, Inc.
11.12.1 Overview
11.12.2 Financial Performance
11.12.3 Product Outlook
11.12.4 Key Developments

12 Appendix
12.1 Related Reports